KOL kliniske forsøg i Georgia
12 studier for KOL søger deltagere på steder i Georgia.
Byer i Georgia
Officiel studietekst (engelsk)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Savannah
- Research Site, Tucker
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 2. okt. 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Appalachian Clinical Research- Site Number : 8400060, Adairsville
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 1. okt. 2026 · NCT07190222To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Centricity Research Columbus, Rincon
RekruttererFase 2
Alder 40 til 85 · Alle køn · Opdateret 30. sep. 2026 · NCT07684820Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Private Practice - Dr. David Kavtaradze- Site Number : 8400006, Cordele
- Primeway Clinical Research- Site Number : 8400121, Fayetteville
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 22. sep. 2026 · NCT07190209A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- Private Practice - Dr. David Kavtaradze- Site Number : 8400017, Cordele
RekruttererFase 4
Alder 40 til 85 · Alle køn · Opdateret 22. sep. 2026 · NCT07053423A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Atlanta
- Research Site, Cordele
- Research Site, Decatur
- og 1 flere
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Atlanta
- Research Site, Lithonia
- Research Site, Rincon
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Cpcc-Research Llc, East Point
- Centricity Research Rincon Pulmonology, Rincon
RekruttererFase 2/3
Alder 35 til 80 · Alle køn · Opdateret 31. aug. 2026 · NCT07363694eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Cordele
- GSK Investigational Site, Dunwoody
RekruttererFase 3
Alder 40 til 75 · Alle køn · Opdateret 28. jul. 2026 · NCT07177339Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
- Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur
RekruttererFase 2
Alder 35 til 89 · Alle køn · Opdateret 15. maj 2026 · NCT05937854Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Adairsville
- GSK Investigational Site, Cordele
- GSK Investigational Site, East Point
- og 1 flere
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 9. apr. 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- SpeciCare, Inc, Gainesville
RekruttererObservationsstudie
Alder 50 og opefter · Alle køn · Opdateret 5. aug. 2025 · NCT06122077Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.